CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-27: PEO Mr. Foster; PEO total compensation $15.44M; PEO compensation actually paid $24.91M; Other NEO average total compensation $3.56M.
- 2024-12-28: PEO total compensation $13.47M; PEO compensation actually paid $3.10M; Other NEO average total compensation $3.50M.
- 2023-12-30: PEO total compensation $14.10M; PEO compensation actually paid $20.47M; Other NEO average total compensation $3.69M.
- 2022-12-31: PEO total compensation $13.45M; PEO compensation actually paid $10.66M; Other NEO average total compensation $3.30M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-27 | Mr. Foster | $15.44M | $24.91M | $3.56M | $4.41M | $81.00 | $148.00 | -$144.34M | Non- GAAP EPS $10.28 | 2026-03-31 |
| 2024-12-28 | $13.47M | $3.10M | $3.50M | $1.14M | $74.00 | $129.00 | $10.30M | $10.32 | 2026-03-31 | |
| 2023-12-30 | $14.10M | $20.47M | $3.69M | $4.93M | $94.00 | $126.00 | $474.62M | $10.67 | 2026-03-31 | |
| 2022-12-31 | $13.45M | $10.66M | $3.30M | $902.29K | $87.00 | $124.00 | $486.23M | $11.12 | 2026-03-31 | |
| 2021-12-25 | $13.71M | $41.20M | $4.39M | $8.87M | $147.00 | $126.00 | $390.98M | $10.32 | 2026-03-31 | |
| 2024-12-28 | Ms. Pease | $13.47M | $6.39M | $3.50M | $1.65M | $123.00 | $147.00 | $10.30M | EPS $10.32 | 2025-04-02 |
| 2023-12-30 | $14.10M | $18.90M | $3.69M | $4.77M | $156.00 | $143.00 | $474.62M | $10.67 | 2025-04-02 | |
| 2022-12-31 | $13.45M | -$11.54M | $3.30M | -$397.97K | $143.00 | $140.00 | $486.23M | $11.12 | 2025-04-02 | |
| 2021-12-25 | $13.71M | $43.17M | $4.39M | $9.21M | $243.00 | $143.00 | $390.98M | $10.32 | 2025-04-02 | |
| 2020-12-26 | $13.48M | $50.02M | $2.77M | $8.86M | $166.00 | $113.00 | $364.30M | $8.13 | 2025-04-02 | |
| 2023-12-30 | Ms. Pease | $14.10M | $18.90M | $3.69M | $4.74M | $156.00 | $143.00 | $474.62M | EPS $10.67 | 2024-03-29 |
| 2022-12-31 | $13.45M | -$11.54M | $3.30M | -$397.97K | $143.00 | $140.00 | $486.23M | $11.12 | 2024-03-29 | |
| 2021-12-25 | $13.71M | $43.17M | $4.39M | $9.21M | $243.00 | $141.00 | $390.98M | $10.32 | 2024-03-29 | |
| 2020-12-26 | $13.48M | $50.02M | $2.77M | $8.86M | $166.00 | $111.00 | $364.30M | $8.13 | 2024-03-29 | |
| 2022-12-31 | Ms. Pease | $13.45M | -$11.54M | $3.30M | -$397.97K | $143.00 | $140.00 | $486.23M | $11.12 | 2023-03-30 |
| 2021-12-31 | $13.71M | $43.17M | $4.39M | $9.21M | $243.00 | $141.00 | $390.98M | $10.32 | 2023-03-30 | |
| 2020-12-31 | $13.48M | $50.02M | $2.77M | $8.86M | $166.00 | $111.00 | $364.30M | $8.13 | 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |